Dual-Pathway Inhibition with Rivaroxaban and Low-Dose Aspirin Does Not Alter Immune Cell Responsiveness and Distribution in Patients with Coronary Artery Disease

ConclusionThree  months of DPI does not result in any meaningful change in immune cell responsiveness and distribution in patients with CAD or PAD.Trial RegistrationClinicalTrials.gov ID: NCT05210725
Source: Cardiology and Therapy - Category: Cardiology Source Type: research